The present invention relates to a kind of medicine that is used for the treatment of lupus erythematosus and photosensitive diseases, especially for the pharmaceutical composition that contains dihydroarteannuin of treatment lupus erythematosus and photosensitive diseases.

Lupus erythematosus and polymorphous light eruption etc. are photosensitive diseases, and lupus erythematosus belongs to immune disease, serious harm health, particularly systemic lupus erythematosus (sle) are often invaded multiple organs such as connective tissue, blood vessel, internal organs, skin and with the systemic disease of crucial immunological abnormality.Modern medicine thinks that autoimmune disease is by the body's immunity disorder, cause the B cell function hyperfunction and produce a large amount of autoantibody, cause that immune complex calm (the lupus kidney often is lethal reason) in basement membrane in the tissue, particularly glomerule causes the III allergic reaction type.

The lupus erythematosus sickness rate has the trend of continuous rising in recent years, and to New York and San Francisco census of population, prevalence is respectively 13.4/10 ten thousand and 50.8/10 ten thousand according to U.S. Siegel and Fessel.Domestic Shanghai textile department census of population prevalence is that 70.4/10 ten thousand (women then is 113.3/10 ten thousand) are so the epidemiology of relevant primary disease and therapeutics research are subjected to domestic and international attention day by day.For the treatment of this disease, doctor trained in Western medicine is used heavy dose of corticosteroid hormone and immunosuppressant treatment more, and to the part patient may command state of an illness, but long-term prescription then causes serious toxic and side effects and complication, even becomes the lethal main cause of primary disease.The traditional Chinese medical science adopts the policy of determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, has developed the medicine of some therapy system lupus erythematosus in recent years.For example Chinese patent application 91103109 discloses a kind of pharmaceutical composition of therapy system lupus erythematosus, wherein contains 34 kinds of Chinese medicines; Chinese patent application 94103378 discloses a kind of pharmaceutical composition of therapy system lupus erythematosus, wherein contains ten plurality of Chinese.Above-mentioned these Chinese medicine compositions all are prescription drugss generally, generally all need the doctor according to patient's practical situation the composition of pharmaceutical composition to be accepted or rejected during use.Although Chinese patent medicine is also arranged, because its composition is many, preparation is complicated, also is not very convenient in actual use therefore.Dihydroarteannuin is the reducing compound of arteannuin, and its structural formula is as follows:...